0000899243-21-045069.txt : 20211117 0000899243-21-045069.hdr.sgml : 20211117 20211117170021 ACCESSION NUMBER: 0000899243-21-045069 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211115 FILED AS OF DATE: 20211117 DATE AS OF CHANGE: 20211117 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Suri Anish CENTRAL INDEX KEY: 0001739130 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38327 FILM NUMBER: 211421303 MAIL ADDRESS: STREET 1: 21 ERIE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cue Biopharma, Inc. CENTRAL INDEX KEY: 0001645460 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 473324577 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 21 ERIE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-949-2680 MAIL ADDRESS: STREET 1: 21 ERIE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: Imagen Biopharma, Inc. DATE OF NAME CHANGE: 20150617 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-11-15 0 0001645460 Cue Biopharma, Inc. CUE 0001739130 Suri Anish C/O CUE BIOPHARMA, INC. 21 ERIE STREET CAMBRIDGE MA 02139 0 1 0 0 President and CSO Common Stock 2021-11-15 4 M 0 8000 8.26 A 102038 D Common Stock 2021-11-15 4 S 0 8000 18.05 D 94038 D Stock Option (right to buy) 8.26 2021-11-15 4 M 0 8000 0.00 D 2025-08-14 Common Stock 8000 10000 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.21, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4. The option vests in eight equal semi-annual installments beginning November 14, 2018. /s/ Anish Suri by Colin Sandercock, attorney-in-fact 2021-11-17